Emmanuelle Schindler

Dr. Emmanuelle Schindler

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2020 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
ESEmmanuelle Schindler
Emmanuelle Schindler
RSR. Andrew Sewell
R. Andrew Sewell
CGChristopher H. Gottschalk
Christopher H. Gottschalk
CLChristina Luddy
Christina Luddy
LFL. Taylor Flynn
L. Taylor Flynn
DDDeepak C. D'SOuza
Deepak C. D'SOuza

20 October 2015 in Journal of Psychoactive Drugs
Verified
Journal Article
Closed access
ESEmmanuelle Schindler
Emmanuelle Schindler
CGChristopher H. Gottschalk
Christopher H. Gottschalk
MWMarsha J. Weil
Marsha J. Weil
RSRobert E. Shapiro
Robert E. Shapiro
DWDouglas A. Wright
Douglas A. Wright
RSRichard Andrew Sewell
Richard Andrew Sewell
Cluster headache is one of the most debilitating pain syndromes. A significant number of patients are refractory to conventional therapies. The Clusterbusters.org medication use survey sought to characterize the effects of both conventional and alternative medications used in cluster headache. Participants were recruited from cluster headache websites and headache clinics. The final analysis included responses from 496 participants. The survey was modeled after previously published surveys and was available online. Most responses were chosen from a list, though others were free-texted. Conventional abortive and preventative medications were identified and their efficacies agreed with those previously published. The indoleamine hallucinogens, psilocybin, lysergic acid diethylamide, and lysergic acid amide, were comparable to or more efficacious than most conventional medications. These agents were also perceived to shorten/abort a cluster period and bring chronic cluster headache into remission more so than conventional medications. Furthermore, infrequent and non-hallucinogenic doses were reported to be efficacious. Findings provide additional evidence that several indoleamine hallucinogens are rated as effective in treating cluster headache. These data reinforce the need for further investigation of the effects of these and related compounds in cluster headache under experimentally controlled settings.

1 March 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
ESEmmanuelle Schindler
Emmanuelle Schindler
RWRyan M. Wallace
Ryan M. Wallace
JSJordan A. Sloshower
Jordan A. Sloshower
DDDeepak C. D’sOuza
Deepak C. D’sOuza
Recent reports on the effects of psychedelic-assisted therapies for mood disorders and addiction, as well as the effects of psychedelics in the treatment of cluster headache, have demonstrated promising therapeutic results. In addition, the beneficial effects appear to persist well after limited exposure to the drugs, making them particularly appealing as treatments for chronic neuropsychiatric and headache disorders. Understanding the basis of the long-lasting effects, however, will be critical for the continued use and development of this drug class. Several mechanisms, including biological and psychological ones, have been suggested to explain the long-lasting effects of psychedelics. Actions on the neuroendocrine system are some such mechanisms that warrant further investigation in the study of persisting psychedelic effects. In this report, we review certain structural and functional neuroendocrinological pathologies associated with neuropsychiatric disorders and cluster headache. We then review the effects that psychedelic drugs have on those systems and provide preliminary support for potential long-term effects. The circadian biology of cluster headache is of particular relevance in this area. We also discuss methodologic considerations for future investigations of neuroendocrine system involvement in the therapeutic benefits of psychedelic drugs.

2 April 2024 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
ESEmmanuelle Schindler
Emmanuelle Schindler
RSR. Andrew Sewell
R. Andrew Sewell
CGChristopher H. Gottschalk
Christopher H. Gottschalk
LFL. Taylor Flynn
L. Taylor Flynn
YZYutong Zhu
Yutong Zhu
DDDeepak C. D'Souza
Deepak C. D'Souza

9 September 2010 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
ARAnthony G. Romano
Anthony G. Romano
JQJennifer L. Quinn
Jennifer L. Quinn
LLLuchuan Li
Luchuan Li
KDKuldip D. Dave
Kuldip D. Dave
ESEmmanuelle Schindler
Emmanuelle Schindler
JHJohn A. Harvey
John A. Harvey

16 June 2022 in Neuropharmacology
Verified
Journal Article
Open access
ESEmmanuelle Schindler
Emmanuelle Schindler
The effects of psychedelic drugs in headache and chronic pain disorders have been reported for several decades, and now controlled studies are emerging. The existing evidence supports a lasting therapeutic benefit after limited dosing, a unique feature of the drug class that distinguishes it from conventional treatment. This commentary summarizes these reports of preventive effects of psychedelic drugs in headache and chronic pain disorders. The recently published controlled trial of psilocybin in migraine is reviewed, including its limitations. Several neurobiological targets of psychedelics that are related to headache and chronic pain are highlighted, though a clear separation of acute and lasting effects is key in uncovering the unique clinical effects of this drug class. Considerable investigation is required before the effects, safety, and mechanism of action of psychedelics in headache and chronic pain disorders can be known.